We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New At-Home Cervical Cancer Screening Device to Increase Accessibility for Patients

By LabMedica International staff writers
Posted on 05 Jun 2025

Cervical cancer is typically linked to certain types of human papillomavirus (HPV), which is passed through sexual contact. More...

While many people are infected with HPV, only a small percentage will develop cervical cancer. Still, screenings are crucial in detecting HPV, cells that may develop into cancer, and cancer. Early intervention is key to saving lives. However, a significant number of cervical cancer diagnoses occur in individuals who haven’t been screened in the previous five years, highlighting a critical access issue in preventive care. Now, researchers have validated a new at-home self-collection device for cervical samples, which has received FDA approval and is shown to be both safe and effective in detecting cervical cancer with high accuracy.

The research, led by the University of Colorado School of Medicine (Aurora, CO, USA), was part of the SELF-CERV trial, a nationwide clinical study involving over 600 participants. The trial was conducted across 16 medical sites in the U.S. and aimed to validate the performance of Teal Wand, which enables individuals to collect cervical cell samples from home by following instructions provided in a mailed kit. These samples are then sent to a lab for analysis. Participants in the trial also underwent traditional in-clinic exams to allow direct comparison of effectiveness. The device not only proved to be easy to use—90% of users completed collection in under five minutes—but it also helped overcome common barriers such as scheduling conflicts, discomfort with pelvic exams, and financial concerns.

Findings revealed that 86% would be more likely to keep up with cervical cancer screening if they could do so at home, and more than 90% preferred the self-collection method offered by the Teal Wand. Survey responses showed that 32% had delayed screenings due to a lack of time, 32% because of discomfort with exams, and another 32% due to financial concerns. The convenience and privacy of the at-home collection method helped mitigate these issues. Beyond increasing screening compliance, the Teal Wand could also benefit physicians and healthcare systems. Physicians can focus on broader aspects of patient health during appointments, confident in the reliability of the self-collection method. This could ultimately lead to earlier detection, fewer missed diagnoses, and a decrease in cervical cancer incidence nationwide.

“Overall, we wanted to make sure that a device like this lived up to the reliability a patient could expect in-clinic,” said Christine Conageski, MD, MSc, the principal investigator for the SELF-CERV trial. “Now, we’ll look at some implementation science and figure out how to integrate this technology into systems across the country, maybe even starting here in Colorado.”

Related Links:
CU School of Medicine


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The VeraBIND Tau assay is a novel blood test that identifies the presence of active tau pathology (Photo courtesy of 123RF)

First Blood-Based Test Measures Key Alzheimer's Biomarker in Asymptomatic and Symptomatic Individuals

Alzheimer’s disease (AD), the sixth leading cause of death in the United States, affects an estimated 7.2 million Americans aged 65 or older. Current diagnostic methods for AD are often invasive, expensive,... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.